- Home
- LIXT vs XBIO Comparison
LIXT vs XBIO Comparison
Compare LIXT & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- XBIO
- Stock Information
- Founded
- LIXT 2005
- XBIO N/A
- Country
- LIXT United States
- XBIO United States
- Employees
- LIXT N/A
- XBIO N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- XBIO Health Care
- Exchange
- LIXT Nasdaq
- XBIO Nasdaq
- Market Cap
- LIXT 6.3M
- XBIO 6.3M
- IPO Year
- LIXT N/A
- XBIO N/A
- Fundamental
- Price
- LIXT $1.27
- XBIO $4.03
- Analyst Decision
- LIXT
- XBIO Hold
- Analyst Count
- LIXT 0
- XBIO 1
- Target Price
- LIXT N/A
- XBIO N/A
- AVG Volume (30 Days)
- LIXT 155.3K
- XBIO 4.7K
- Earning Date
- LIXT 03-18-2025
- XBIO 03-20-2025
- Dividend Yield
- LIXT N/A
- XBIO N/A
- EPS Growth
- LIXT N/A
- XBIO N/A
- EPS
- LIXT N/A
- XBIO N/A
- Revenue
- LIXT N/A
- XBIO $2,523,427.00
- Revenue This Year
- LIXT N/A
- XBIO N/A
- Revenue Next Year
- LIXT N/A
- XBIO N/A
- P/E Ratio
- LIXT N/A
- XBIO N/A
- Revenue Growth
- LIXT N/A
- XBIO 7.15
- 52 Week Low
- LIXT $1.25
- XBIO $2.78
- 52 Week High
- LIXT $4.40
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- LIXT 28.82
- XBIO 45.61
- Support Level
- LIXT $1.35
- XBIO $3.91
- Resistance Level
- LIXT $3.00
- XBIO $4.24
- Average True Range (ATR)
- LIXT 0.26
- XBIO 0.17
- MACD
- LIXT -0.13
- XBIO -0.01
- Stochastic Oscillator
- LIXT 1.15
- XBIO 28.93
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.